A:NYE-Agilent Technologies Inc.

EQUITY | Medical Diagnostics & Research | New York Stock Exchange

Last Closing

USD 71.93

Change

0.00 (0.00)%

Market Cap

USD 14.27B

Volume

1.55M

Analyst Target

USD 79.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agilent Technologies Inc provides application focused solutions that includes instruments, software, services and consumables for the entire laboratory workflow for life sciences, diagnostics and applied chemical markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-20 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing A

TECX:CA TD Global Technology Lead.. 99.42 % 0.00 %

N/A

CAD 2.41M
HHL:CA Harvest Healthcare Leader.. 5.05 % 1.15 %

+0.05 (+0.35%)

CAD 0.33B
EDOC:LSE Global X Telemedicine & D.. 4.67 % 0.00 %

+0.07 (+0.35%)

USD 5.15M
EDOG:LSE Global X Telemedicine & D.. 4.62 % 0.00 %

+0.04 (+0.35%)

USD 5.15M
DDOC:F Global X Telemedicine & D.. 4.53 % 0.00 %

+0.09 (+0.35%)

USD 5.15M
EDOC:SW Global X Telemedicine & D.. 4.53 % 0.00 %

+0.03 (+0.35%)

USD 5.11M
AHOY Tidal ETF Trust 4.44 % 0.00 %

+0.22 (+0.35%)

USD 2.91M
GNOM:SW Global X Genomics & Biote.. 4.23 % 0.00 %

+0.09 (+0.35%)

USD 8.88M
GNOG:LSE Global X Genomics & Biote.. 4.02 % 0.00 %

+0.06 (+0.35%)

USD 7.58M
GN0M:XETRA Global X Genomics & Biote.. 3.93 % 0.00 %

+0.10 (+0.35%)

USD 8.88M
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.44 % 0.00 %

+0.06 (+0.35%)

USD 0.05B
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.44 % 0.00 %

+0.04 (+0.35%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.44 % 0.00 %

+0.02 (+0.35%)

N/A
ABIE:XETRA AXA IM ACT Biodiversity E.. 2.41 % 0.00 %

N/A

N/A
ABIT:XETRA AXA IM ACT Biodiversity E.. 2.37 % 0.00 %

+0.01 (+0.35%)

USD 0.40B
ABIT:F AXA IM ACT Biodiversity E.. 2.29 % 0.00 %

N/A

N/A
ABIE:F AXA IM ACT Biodiversity E.. 2.29 % 0.00 %

+0.04 (+0.35%)

N/A
VSDA VictoryShares Dividend Ac.. 2.14 % 0.35 %

+0.76 (+0.35%)

USD 0.26B
HEAL:SW iShares Healthcare Innova.. 1.54 % 0.00 %

+0.05 (+0.35%)

N/A
FIW First Trust Water ETF 0.00 % 0.55 %

+1.57 (+0.35%)

USD 1.47B
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.03 (+0.35%)

CAD 0.05B
GOAT 0.00 % 0.00 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.23 (+0.35%)

USD 0.10B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

+0.03 (+0.35%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.03 (+0.35%)

USD 1.14B
TOCA:CA TD One-Click Aggressive E.. 0.00 % 0.00 %

N/A

CAD 0.03B
TOCC:CA TD One-Click Conservative.. 0.00 % 0.00 %

N/A

CAD 0.01B
TOCM:CA TD One-Click Moderate ETF.. 0.00 % 0.00 %

N/A

CAD 0.02B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

+0.15 (+0.35%)

USD 0.05B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

+0.08 (+0.35%)

USD 5.15M
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

N/A

N/A
GOAT:LSE VanEck Morningstar Global.. 0.00 % 0.00 %

+0.02 (+0.35%)

USD 0.06B
GOGB:LSE VanEck Morningstar Global.. 0.00 % 0.00 %

+0.05 (+0.35%)

USD 0.07B
XGEN:XETRA Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

+0.25 (+0.35%)

USD 3.60M

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.63% 47% F 49% F
Dividend Return N/A N/A N/A N/A F
Total Return 6.63% 47% F 49% F
Trailing 12 Months  
Capital Gain -1.56% 53% F 75% C
Dividend Return 0.84% 67% D+ 13% F
Total Return -0.72% 53% F 65% D
Trailing 5 Years  
Capital Gain 18.48% 21% F 67% D+
Dividend Return 30.13% 86% B+ 81% B-
Total Return 48.61% 29% F 75% C
Average Annual (5 Year Horizon)  
Capital Gain 12.21% 41% F 84% B
Dividend Return 12.73% 35% F 81% B-
Total Return 0.51% 29% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 18.11% 47% F 40% F
Risk Adjusted Return 70.25% 35% F 70% C-
Market Capitalization 14.27B 76% C+ 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.90 24% 6%
Price/Book Ratio 5.01 24% 13%
Price / Cash Flow Ratio 5.98 53% 17%
Price/Free Cash Flow Ratio 25.33 53% 20%
Management Effectiveness  
Return on Equity 6.92% 41% 45%
Return on Invested Capital 14.58% 76% 72%
Return on Assets 3.68% 47% 59%
Debt to Equity Ratio 42.75% 65% 67%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector